A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Batuman, Backes, Beaudoin, Beckman, Belancio, Berenson, Betancourt, Blake, Blaya, Boh, Bunnell, Burdsal, Burow

Vecihi Batuman, M.D.

Professor of Medicine
Section of Nephrology
TCC Program Member
vbatuma@tulane.edu
(504) 988-5346, (504) 988-1909 fax
1430 Tulane Ave., Box SL-45, New Orleans, LA 70112-2699
Homepage on the Nephrology website:
http://www.som.tulane.edu/departments/nephrology/batuman.html



Biographical Narrative:

Dr. Batuman received his MD from Hacettepe University Medical School in Ankara, Turkey and completed his Internal Medicine and Nephrology training at Jersey City Medical Center, New Jersey Medical School. He was a full-time faculty member and Chief of the Renal Hypertension program in East Orange Veterans Affairs Medical Center before he joined the Tulane Program. He served as the President of the New Jersey Society of Nephrology in 1982. Dr. Batuman is certified in Internal Medicine and Nephrology by the American Board of Internal Medicine and Nephrology and is recognized as Hypertension Specialist by the American Society of Hypertension. He is a Fellow of the American College of Physicians and a member of many professional societies including the American Society of Nephrology, International Society of Nephrology and American Society of Hypertension. His current laboratory research focuses on myeloma light chain metabolism and toxicity in kidney cells, endocytic receptors that mediate endocytosis and metabolism of filtered myeloma proteins in the kidney and the role of cytokines and transcription factors in the pathogenesis of kidney disease in myeloma. Dr. Batuman's other research interests include hypertension, lead nephropathy, Balkan endemic nephropathy, environmental kidney disease and dialysis.



Selected Publications:

  • Batuman V, Guan S. Receptor-mediated endocytosis of immunoglobulin light chains in cultured proximal tubule cells. Am J Physiol 272 (Renal Physiol 41):F521-F530 (1997)
  • Puschett, J.B., Batuman V. Hypertension and the kidney: Medical Intelligence. Cardiovasc Risk Factors 7:7-16 (1997)
  • Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Simon E, Pontillon F, Lyles M, Bruno J, Hammond TG. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol (Renal Physiol 44): F246-F254 (1998)
  • Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V. Cyclosporine associated thrombotic microangiopathy in renal allografts. Kidney Int 55: 2457-2466 (1999)
  • Guan S, El-Dahr S, Dipp S, Batuman V. Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Invest Med 47: 496-501 (1999)
  • Pote A, Zwizinski C, Guan S, Simon EE, Batuman V. Cytotoxicity of myeloma light chains in cultured human proximal tubule cells. Am J Kidney Dis 36: 735-744 (2000)

Backes, Wayne L
Professor/Associate Dean for Research

Positions and Employment

  • 1981-Nov. 1983 Instructor of Pharmacology, Univ. Connecticut Health Center, Farmington, CT
  • Dec. 1983 - June 1984 Res. Asst. Prof. Dept. of Pharmacology, Univ. Conn. Health Ctr., Farmington, CT
  • July 1984 - July 1989 Assistant Professor, Dept. of Pharmacology, LSU Medical Center, New Orleans, LA
  • July 1989 - 1995 Associate Professor, Department of Pharmacology and Experimental Therapeutics, Louisiana State University Medical Center, New Orleans, LA
  • July 1995 - present Professor, Dept. of Pharmacology, LSUHSC, New Orleans, LA
  • Jan. 1999 - 2001 Acting Head, Department of Pharmacology, LSUMC, New Orleans, LA
  • October 2001 – present Associate Dean for Research, LSU Health Sciences Center, New Orleans, LA
  • 1996, 2002 Merit Reviewer for Veterans Administration Grant Proposals
  • July 1999 – June 2002 Secretary-Treasurer for the Division for Drug Metabolism (Division of ASPET)
  • 2002 – 2004 National Center for Complementary and Alternative Medicine NIH (study section)
  • 2003 National Institute of Environmental Health Sciences – Environmental Health Center Review Site Visit Committee, National Institutes of Health
  • 2004, 2006, 2007 National Institutes of Health, Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section (ad hoc)
  • Oct. 2004 – April 2005 National Institute of Environmental Health Sciences – Superfund Basic Research and Training Program – Center Reviews, National Institutes of Health
  • April 2004 – 2005 National Institute of Environmental Health Sciences – Special Emphasis Panel (Review of Superfund Supplements), National Institutes of Health
  • Jan. 2006 – present External Advisory Committee, Center for the Study of Botanicals and Metabolic Syndrome., Pennington Biomedical Research Center and Rutgers University; NCCAM, January 2006 – present
  • March 2008 NIH-NIAAA - IAR activated for Special Emphasis Panel (SEP) ZAA1 JJ (17), “RFA AA-08-001 / -002: The Role of Mitochondria in Alcohol-Induced Tissue Injury”
  • July 2008 – present Secretary-Treasurer for the Division for Toxicology (Division of ASPET)
  • Jan. 2009 – present Xenobiotic and Nutrition Disposition and Action Study Section, National Institutes of Health

Selected Publications:

  • Sequeira, D.J., Eyer, C.S. Cawley, G.F., Nick, T.G. and Backes, W.L. (1992) Ethylbenzene-mediated Induction of Cytochrome P450 Isozymes in Male and Female Rats. Biochem. Pharmacol. 44, 1171-1182.
  • Backes, W.L., Sequeira, D.J., Cawley, G.F., and Eyer, C.S. (1993) Relationship Between Hydrocarbon Structure and Induction of Cytochrome P450: Effects on Protein Levels and Enzyme Activities.
    Xenobiotica 23, 1353-1366.
  • Backes, W.L., Cawley, G., Eyer, C.S., Means, M., Causey, K.M. and Canady, W.J. (1993) Aromatic Hydrocarbon Binding to Cytochrome P450 and Other Enzyme Binding Sites: Are Hydrophobic Compounds Drawn into the Active Site or Pushed from the Aqueous Phase? Arch. Biochem. Biophys. 304, 27-37.
  • Sequeira, D.J., Cawley, G.F., Eyer, C.S., and Backes, W.L. (1994) Temporal Changes in P-450 2E1 Expression with Continued Ethylbenzene Exposure. Biochim. Biophys. Acta 1207, 179-186.
  • Yuan, W., Cawley, G.F., Eyer, C.S., and Backes, W.L. (1994) Induction of P450 3A by Ethylbenzene Without Altering RNA Levels. Biochem. Biophys. Res. Commun. 202, 1259-1265.
  • Yuan, W., White, T.B., Yuan, W., White, J.W., Strobel, H.W., and Backes, W.L. (1995) Relationship Between Hydrocarbon Structure and Induction of Cytochrome P450: Effect on RNA Levels. Xenobiotica 25, 9-16.
  • Cawley, G.F., Batie, C.J., and Backes, W.L. (1995) Substrate-Dependent Competition of Different P450 Isozymes for Limiting NADPH-Cytochrome P450 Reductase. Biochemistry 34, 1244-1247.
  • Yuan, W., Serron, S.C., Cawley, G.F., Eyer, C.S., and Backes, W.L. (1997) Ethylbenzene Modulates the Expression of Different Cytochrome P450 Isozymes by Unique Multistep Processes. Biochim. Biophys. Acta 1334, 361-372.
  • Yuan, W., Sequeira, D.J., Cawley, G.F., Eyer, C.S., and Backes, W.L. (1997) Time Course for the Modulation of Cytochrome P450 After Administration of Ethylbenzene and its Correlation with Toluene Metabolism. Arch. Biochem. Biophys. 339, 55-63.
  • Bergeron1, R.M., Serron, S.C., Rinehart, J.J., Cawley, G.F., and Backes, W.L. (1998) Pituitary Component of the Ethylbenzene-Mediated Expression of Cytochrome P450s 2B1, 2B2 and 2C11. Xenobiotica 28, 303-312.
  • Backes, W.L., Batie, C.J., and Cawley, G.F. (1998) Interactions Among P450 Isozymes: Evidence for the Existence of a 2B4-1A2-Reductase Complex with Altered Catalytic Function. Biochemistry 37, 12852-12859.
  • Bergeron, R.M., Desai, K., Serron, S.C., Cawley, G.F., Eyer, C.S. and Backes, W.L., (1999) Changes in the Expression of Cytochrome P450s 2B1, 2B2, 2E1, and 2C11 in Response to Daily Aromatic Hydrocarbon Treatment. Toxicol. Applied Pharmacol. 157, 1-8.
  • Serron, S.C., Dwivedi, N., and Backes, W.L. (2000) Ethylbenzene Induces Microsomal Oxygen Free Radical Generation: Antibody-directed characterization of the responsible cytochrome P450 isozymes. Toxicol. Applied Pharmacol. 164, 305-311.
  • Serron, S.C., Zhang, S., Bergeron, R.M., and Backes, W.L., (2001) Effect of Hypophysectomy and Growth Hormone Replacement on the Modulation of P450 Expression after Treatment with the Aromatic Hydrocarbon Ethylbenzene Toxicol. Applied Pharmacol. 172, 163-171.
  • Backes, W.L., Zhang, S., and Cawley, G.F., (2001) Evidence supporting the interaction of P450 2B4 and 1A2 in microsomal preparations Drug Metabol. Dispos. 29, 1529-1534.
  • Backes, W.L. and Serron, S.C., (2001) Invited response to a letter to the editor regarding “Ethylbenzene Induces Microsomal Oxygen Free Radical Generation: Antibody-directed characterization of the responsible cytochrome P450 isozymes”. Toxicol. Applied Pharmacol. 173, 189-189.
  • Zhang, S., Cawley, G.F., Eyer, C.S., and Backes, W.L. (2002) Altered Ethylbenzene-Mediated Hepatic CYP2E1 Expression in Growth Hormone Deficient Dwarf Rats. Toxicol. Applied Pharmacol. 179, 74-82.
  • Hunt, J.D., Strimas, A., Martin, J.E., Eyer, M., Haddican, M., Luckett, B.G., Ruiz, B., Axelrad, T. W., Backes, W.L., and Fontham, E.T.H. (2002) Differences in KRAS Mutation Spectrum in Lung Cancer Cases between African Americans and Caucasians after Occupational or Environmental Exposure to Known Carcinogens. Canc. Epidem. Biomarkers Prev. 11, 1405-1412.
  • Backes, W.L. and Kelley, R.W. (2003) Organization of Multiple Cytochrome P450s and NADPH-cytochrome P450 Reductase in Lipid Membranes, Pharmacol. Ther., 98, 221-233.
  • Cheng, Dongmei, Kelley, R.W., Cawley, G.F., and Backes, W.L. (2004) High Level Expression of Recombinant Rabbit Cytochrome P450 2E1 in Escherichia coli C41 and Its Purification. Prot. Express. Purific. 33, 66-71.
  • Kelley, R.W., Reed, J.R. and Backes, W.L. (2005) Effects of Ionic Strength on the Functional Interactions between CYP2B4 and CYP1A2. Biochemistry, 44, 2632-2641.
  • Backes, W.L., Kelley, R.W., Cheng, D., and Reed, J.R. (2005) How are NADPH-cytochrome P450 Reductase and Multiple Cytochromes P450 Organized in Membranes? Proceedings from the 14th International Conference on Cytochrome P450: Biochemistry, Biophysics and Bioinformatics 163-170.
  • Reed, J.R., Kelley, R.W., and Backes, W.L. (2006) An Evaluation of Methods for the Reconstitution of Cytochromes P450 and NADPH P450 Reductase into Lipid Vesicles. Drug Metab. Dispos. 34, 660-666.
  • Cormier, S.A., Lomnicki, S., Backes, W., and Dellinger, B. (2006) Origin and Health Impacts of Emissions of Toxic By-Products and Fine Particles from Combustion and Thermal Treatment of Hazardous Wastes and Materials. Environmental Health Persp. 114, 1-10.
  • Kelley, R.W., Cheng, D., and Backes, W.L. (2006) Heteromeric Complex Formation Between CYP2E1 and CYP1A2: Evidence for the Involvement of Electrostatic Interactions. Biochemistry 45, 15807-15816.
  • Cheng, D., Reed, J.R. Harris, D., and Backes, W.L. (2007) Inhibition of CYP2B4 by the Mechanism-based inhibitor 2-Ethynylnaphthalene: Inhibitory Potential of 2EN is Dependent on Substrate Size. Arch. Biochem. Biophys. 462, 28-37.
  • Cheng, D., Harris, D., Reed, J.R. and Backes, W.L. (2007) Inhibition of CYP2B4 by the Mechanism-based inhibitor 2-Ethynylnaphthalene: Evidence for the Co-Binding of Substrate and Inhibitor within the Active Site. Arch. Biochem. Biophys. 468, 174-182.
  • Huber, W.J. and Backes, W.L. (2007) Expression and Characterization of Full-Length Human Heme Oxygenase-1: Presence of intact membrane-binding region leads to increased binding affinity for NADPH-cytochrome P450 reductase. Biochemistry 46(43); 12212-12219.
  • Huber, W.J. and Backes, W.L. (2008) Quantitation of Heme Oxygenase-1: Heme Titration Increases Yield of Purified Protein, Anal. Biochem. 373, 167-169.
  • Reed, J.R., Brignac-Huber, L.M., Backes, W.L. (2008) Physical Incorporation of NADPH-cytochrome P450 Reductase and Cytochrome P450 into Phospholipid Vesicles using Glycocholate and Biobeads. Drug Metab. Dispos. 36, 582–588.
  • Huber III, W.J., Scruggs, B., and Backes, W.L. (2009) C-Terminal Membrane Spanning Region of Human Heme Oxygenase-1 Mediates a Time Dependent Complex Formation with Cytochrome P450 Reductase, Biochemistry 41, 190-197.
  • Huber III, W.J., Marohnic, C.C., Peters, , M., Alam, J., Masters, B.S.S., and Backes, W.L. (2008) Measurement of Membrane-Bound Human Heme Oxygenase-1 Activity Using a Chemically Defined Assay System , Drug Metab. Dispos. (in press).


Back to the top

Christopher E. Beaudoin, Ph.D.

Assistant Professor of Community Health Sciences
TCC Associate Member
beaudoin@tulane.edu
(504) 988-4538, (504) 988-3540 fax
1430 Tulane Ave., SL-29, New Orleans, LA 70112-2699

Selected Publications:

  • Beaudoin CE, Thorson E. Credibility perceptions of news coverage of ethnic groups: the predictive roles of race and news use. The Howard Journal of Communications, 16(1): 33-48, 2005.
  • Beaudoin CE. Exploring antismoking ads: appeals, themes and consequences. Journal of Health Communication, 7(2): 123-137, 2002.
  • Thorson E, Beaudoin CE. The impact of a health campaign on health social capital. Journal of Health Communication, 9(3): 167-194, 2004.
  • Beaudoin CE, Thorson E. Social capital in rural and urban communities: testing differences in media effects and models. Journalism & Mass Communication Quarterly, 81(2): 378-399, 2004.
  • Beaudoin CE, Thorson E. Testing the cognitive mediation model: the roles of news reliance and three gratifications sought. Communication Research, 31(4): 446-471, 2004

Back to the top

Barbara S. Beckman, Ph.D.

Professor of Pharmacology
TCC Contributing Member
bbeckman@tulane.edu
Homepage on the Pharmacology website:
http://www.som.tulane.edu/departments/pharmacology/Faculty/Beckman.html
(504) 988-5444
1430 Tulane Ave., Box SL-83, New Orleans, LA 70112-2699


Biographical Narrative:

Dr. Beckman received her B.S. from Tulane University in 1968. She completed her doctorate in pharmacology from Johns Hopkins University School of Medicine in 1978. Her postdoctoral fellowship was completed under the direction of Dr. James Fisher in the area of erythropoietin signal transduction mechanisms. In 1980 Dr. Beckman became a faculty member in the Department of Pharmacology, initially as a Research Assistant Professor, ultimately rising to the rank of tenured Professor in 1994. Dr. Beckman has served as Co-Director and Director of the Molecular and Cellular Biology Interdisciplinary Graduate Program and has served as reviewer for the American Heart Association, NIH AIDS and related Research Study Section, Endocrinology Study Section and USAMRMC Breast Cancer Research Program. She is currently Adjunct Professor in Otolaryngology as well as Physiology. Dr. Beckman is a member of the American Association for Cancer Research as well as the American Society for Pharmacology and Experimental Therapeutics.She has served as a member and Chair of the ASPET Graduate Recruitment and Education Committee. She was elected as a Fellow of the American Association for the Advancement of Science in 2005. Dr. Beckman's primary research interests focus on understanding molecular and biochemical mechanisms of chemoresistance in breast cancer as well as hypoxia-regulated gene expression related to erythropoietin and to angiogenesis.



Selected Publications:

Back to the top

Victoria Perepelitsa BelancioVictoria Perepelitsa Belancio, Ph.D.

Research Assistant Professor of Structural and Cellular Biology Member of the Tulane Center for Aging TCC Program Member
vperepe@tulane.edu
504-988-4506, 504-988-5516(fax)
1430 Tulane Ave., SL49, New Orleans, LA 70112
Faculty listing on the Structural and Cellular Biology website: http://www.som.tulane.edu/departments/scb/

Biographical Narrative:

Dr. Belancio was born in Berlin, Germany. She obtained her BS and MS degrees in Cytology and Genetics from Novosibirsk State University in Novosibirsk, Russia. She studied Medical Genetics at the University of Alabama at Birmingham. She received her doctoral degree in Molecular and Cellular biology from the Department of Epidemiology at Tulane University in New Orleans. She did her postdoctoral training with Dr. Prescott Deininger at Tulane University. She has been a faculty member in the Department of Structural and Cellular Biology, Tulane School of Medicine since 2008 and is a member of the Tulane Center for Aging. Dr. Belancio's primary research interests are focused on genetic instability and cellular responses associated with the activity of mammalian retroelements. She is studying molecular mechanisms controlling the expression of and the damage from these elements in normal and cancer cells.


Selected publications:

  • Wertz GW, Perepelitsa VP, Ball LA. Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7):3501-6.

  • Ball LA, Pringle CR, Flanagan B, Perepelitsa VP, Wertz GW. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virology 1999 Jun; 73(6):4705-12.
  • Perepelitsa-Belancio V, Deininger P. RNA truncation by premature polyadenylation attenuates human mobile element activity. Nat Genetics 2003 Dec; 35(4):363-6. [commentaries in "The Scientist and Nature Reviews Genetics"]
  • Astrid M. Roy-Engel, Mohamed El-Sawy, Lubna Farooq, Guy L. Odom, Victoria Perepelitsa-Belancio, Heather Bruch, Oluwatosin O. Oyeniran, and Prescott L. Deininger. Human Retroelements May Introduce Intragenic Polyadenylation Signals. Cytogenetic and Genome Research, 2005;110(1-4):365-71.
  • Mohammed El-Sawy, Shubha Kale, Christine Dugan, Thuc Quyen Nguyen, Victoria Perepelitsa-Belancio, Heather Bruch, Astrid M. Roy-Engel, and Prescott L. Deininger. Nickel stimulates genetic instability through L1 retrotransposition. Journal of Molecular Biology, 2005 Nov 25;354(2):246-57.
  • Belancio VP., Hedges DJ., Deininger P. LINE-1 RNA splicing and influences on mammalian gene expression. Nucleic Acid Research. 2006 Mar 22; 34(5):1512-1521
  • Jinchuan Xing, Hui Wang, Victoria P. Belancio, Richard Cordaux, Prescott Deininger and Mark A. Batzer. "Emergence of new primate genes by retrotransposon-mediated sequence transduction" Proc Natl Acad Sci USA. 2006 Nov 21;103(47):17608-13.
  • Belancio VP., Whelton M., Deininger P. Requirements for polyadenylation at the 3' end of LINE-1 element. Gene. 2007 Apr 1;390(1-2):98-107
  • Belancio VP., D. Hedges, and Deininger P. Mammalian non-LTR retrotransposons: For better or worse, in sickness and in health. Review. Genome Research 2008 Mar;18(3):343-58
  • Belancio VP., Roy-Engel AM., Deininger P. The impact of multiple splice sites in human L1 elements. Gene. 2008 411(1-2):38-45
  • Wallace NA., Belancio VP., and Deininger P. L1 mobile element expression causes multiple types of toxicity. Gene 2008 Aug 1;419(1-2):75-81

Back to the top

Gerald S. Berenson, M.D.

Clinical Professor of Medicine, Section of Cardiology
Clinical Professor of Pediatrics, Section of Pediatric Cardiology
Research Professor of Epidemiology
Director of the Tulane Center for Cardiovascular Health
Chair in Preventitive Cardiology
Principal Investigator, Bogalusa Heart Study
TCC Associate Member
berenson@tulane.edu
(504) 988-7197, (504) 988-7194 fax
1430 Tulane Ave., Box SL-29, New Orleans, LA 70112-2699
Homepage on the Cardiology website:
http://www.cardiology.tulane.edu/berenson.html
Homepage on the Epidemiology website:
http://www.epidemiology.tulane.edu/epi_pages/faculty/berenson.html



Biographical Narrative:

Dr. Berenson, a native of Bogalusa, Louisiana, is a graduate of Tulane University and the Tulane School of Medicine. He has taught as a cardiologist at both Louisiana State University and Tulane University Medical Schools for over 40 years. He was Section Chief of Cardiology at LSU Medical Center for 17 years. His primary interest is in atherosclerosis, coronary artery disease, and hypertension. He is the Principal Investigator of the Bogalusa Heart Study, which has become known nationally and internationally for the study of the early natural history of heart disease. As an outgrowth of observations of poor lifestyles, unhealthy diet, smoking and inactivity contributing to obesity, he and his colleagues developed a prevention program for elementary school children, the Health Ahead/Heart Smart health education program, and a Family Health Program to control cardiovascular risk factors. Dr. Berenson's interest is in the prevention of heart disease and he encourages health education of children and families as a public health approach for preventive cardiology.



Selected Publications:
  • Srinivasan SR, Myers L, Berenson GS. Risk variables of insulin resistance syndrome in African-American and Caucasian young adults with microalbuminuria: The Bogalusa Heart Study. Am J Hyperten 13: 1271-1279 (2000)
  • Batten LA, Urbina EM, Berenson GS. Interobserver reproducibility of heart rate variability in children: The Bogalusa Heart Study. Am J Cardiol 86: 1264-1266 (2000)
  • Chen W, Srinivasan SR, Berenson GS. Plasma renin activity and insulin resistance in African-American and white children: The Bogalusa Heart Study. Am J Hyperten 14: 212-217 (2001)
  • Srinivasan SR, Myers L, Berenson GS. Rate of change in adiposity and its relationship to concomitant changes in cardiovascular risk variables among biracial (black-white) children and young adults: The Bogalusa Heart Study. Metabolism 50: 299-305 (2001)
  • Freedman DS, Bowman BA, Srinivasan SR, Berenson GS, Otvos JD. Distribution and correlates of high-density lipoprotein subclasses among children and adolescents. Metabolism 50: 370-376 (2001)
  • Frontini MG, Srinivvasan SR, Elkasabany A, Berenson GS. Distribution and cardiovascular risk correlates of serum triglycerides in young adults for a biracial community: The Bogalusa Heart Study. Atherosclerosis 155: 201-209 (2001)

Back to the top

Aline M. Betancourt, PhD
Research Associate Professor

Positions and Employment

  • Present Research Associate Professor, Dept. of Microbiology, Tulane University Medical Center, New Orleans, LA
  • 1999-2006 Research Assistant Professor, Dept. of Microbiology, Tulane University Medical Center, New Orleans, LA.
  • 1999 Research Assistant Professor, Dept. of Pharmacology, Tulane University Medical Center, New Orleans, LA.
  • 1997- 1999 Research Instructor, Dept. of Pharmacology, Tulane University Medical Center, New Orleans, LA.
  • 1994- 1997 Postdoctoral Fellow, Tulane Cancer Center, Department of Pharmacology, Tulane University Medical Center, New Orleans, LA.
  • 1992-1993:  Postdoctoral Fellow, Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, National

Selected Publications

  • Lichti, U., Scandurro, A.B.; Kartasova, T., Rubin, J.S., LaRochelle, W.; and Yuspa, S.H. (1994) Hair follicle development and hair growth from defined cell populations grafted onto nude mice. J. Invest. Dermatol. 104(5 Suppl): 43S-44S.
  • Kartasova, T; Scandurro, A.B.; Denning, M.F.; Wirth, PJ.; Yuspa, S.H. and Lichti, U. (1994) Factors mediating the interactions between epidermal and dermal cells in skin grafts which might be important for hair follicle development. J. Invest. Dermatol. 104(5 Suppl):21S-22S.
  • Rondon, I.J.; Scandurro, A.B.; Wilson, R.B. and Beckman, B.S. (1995) Changes in redox affect the activity of erythopoietin RNA binding protein. FEBS Letters 359: 267-270.
  • Scandurro, A.B., Wang, Q., Goodman, L., Ledbetter S., Dooley, T.P., Yuspa, S.H., and Lichti, U. (1995) Immortalized rat whisker dermal papilla cells cooperate with mouse immature hair follicle buds to activate type IV procollagenase in collagen matrix coculture: correlation with ability to promote hair follicle development in nude mouse grafts. J. Invest. Dermatol. 105: 177-183.
  • Scandurro, A.B., McGary, E., Rondon, I.J., Wilson, R., and Beckman, B.S. (1995) Redox and heat shock protein HSP70 affect the binding of erythropoietin RNA binding protein to erythropoietin mRNA.  Acta Hematologica 93: 216.
  • Scandurro, A.B., Rondon, I.J., Wilson R.B., Tennenbaum, S.A., Garry, R.F., and Beckman, B.S. (1997) Interaction of erythropoietin RNA binding protein with mRNA requires an association with heat shock protein 70. Kidney Int. 51(2): 579-584.
  • Mallia CM, Aguirre, V, McGary E, Tang Y, Scandurro AB, Liu C, Noguchi CT, Beckman B.S.  (1998) Protein kinase C a is an effector of hexamethylene bisacetamide-induced differentiation of friend erythroleukemia cells. Exp. Cell Res. 246:348-354.
  • Scandurro, A.B. and Beckman B.S. (1998) Common Proteins bind mRNAs encoding Erythropoietin, Tyrosine Hydroxylase and Vascular Endothelial Growth Factor. Biochem.Biophys.Res.Comm. 246:436-440.
  • Ohigashi T, Mallia CS, McGary E, Scandurro A.B., Rondon I, Fisher JW, Beckman BS (1999) Protein kinase C alpha protein expression is necessary for sustained erythropoietin production in human hepatocellular carcinoma (Hep3B) cells exposed to hypoxia. Biochim Biophys Acta  1450(2):109-18.
  • Godin DA, Fitzpatrick PC, Scandurro A.B., Belafsky PC, Woodworth BA, Amedee RG, Beech DJ, Beckman BS. (2000) PH20: a novel tumor marker for laryngeal cancer. Arch Otolaryngol Head Neck Surg.  126(3):402-4.
  • Scandurro, A.B., Weldon, C.W., Gutierrez, Y.I., Alam, J. and Beckman, B.S. (2001) Gene microarray  analysis reveals a novel hypoxia signal transduction pathway  in human hepatocellular carcinoma cells . Intl. J. Oncol. 19:129-135.
  • Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME. (2002) Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery. 132(2): 293-301.
  • Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS (2002) NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol. 30(12):1419-27.
  • Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA. (2004) Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway.Carcinogenesis.  Feb;25(2):249-61. Epub 2003 Nov 06.
  • Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, McLachlan JA, Burow ME, Beckman BS. (2005) PKC-mediated survival signaling in breast carcinoma cells: A role for MEK1-AP1 signaling. Int J Oncol. Mar;26(3):763-8.
  • Lamarca HL, Ott CM, Honer Zu Bentrup K, Leblanc CL, Pierson DL, Nelson AB, Scandurro AB, Whitley GS, Nickerson CA, Morris CA. (2005) Three-dimensional growth of extravillous cytotrophoblasts promotes differentiation and invasion. Placenta. 26(10):709-20. Epub 2005 Jan 25.
  • Lamarca HL, Nelson AB, Scandurro AB, Whitley GS, Morris CA. (2006) Human cytomegalovirus-induced inhibition of cytotrophoblast invasion in a first trimester extravillous cytotrophoblast cell line. Placenta. 27(2-3):137-47.
  • Weldon, C. B., A. McKee, B. M. Collins-Burow, L. I. Melnik, A. B. Scandurro, J. A. McLachlan, M. E. Burow, B. S. Beckman. 2005. PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling. Int. J. Oncol. 26(3):763-8.
  • Elizabeth R. Abboud, Seth B. Coffelt, Yanira G. Figueroa, Kevin J. Zwezdaryk, Anne B. Nelson, Deborah E. Sullivan, Cindy B. Morris, Yan Tang, Barbara S. Beckman and Aline B. Scandurro. Integrin-Linked Kinase: A Hypoxia Induced Anti-Apoptotic Factor Exploited By Cancers. 2007. Int. J. Oncol. 30:113-122.
  • Seth B. Coffelt, Ruth S. Waterman, Luisa Florez, Kevin J. Zwezdaryk, Kerstin Honer zu Bentrup, Suzanne L. Tomchuck, Heather L. LaMarca, Yanira I. Gutierrez-Figueroa, Elizabeth S. Danka, and Aline B. Scandurro. hCAP-18/LL-37:  A Novel Player in Cancers of the Ovary. 2008 Int J Cancer. Mar 1;122(5):1030-9.
  • Kevin J. Zwezdaryk, Seth B. Coffelt, Yanira G. Figueroa, Juliet Liu, Donald G. Phinney, Heather L. LaMarca, Luisa Florez, Cindy B. Morris, Gary W. Hoyle and Aline B. Scandurro. Erythropoietin a Hypoxia-Regulated Factor Elicits a Pro-Angiogenic Program in Human Mesenchymal Stem Cells. Experimental Hematology. 2007 Apr;35(4):640-52.
  • Suzanne L. Tomchuck, Kevin J. Zwezdaryk, Seth B. Coffelt, Ruth S. Waterman, and Aline B. Scandurro. Toll-Like Receptors on Human Mesenchymal Stem Cells Drive their Stress Signal Responses. Stem Cells Stem Cells. 2008 Jan;26(1):99-107. Epub 2007 Oct 4.
  • Seth B. Coffelt and Aline B. Scandurro. (2008) Tumors sound the alarmin(s).
    Cancer Res. Aug 15;68(16):6482-5.
  • Seth B. Coffelt, Ruth S. Waterman, Kevin J. Zwezdaryk, Kerstin Honer zu Bentrup, Suzanne L. Tomchuck, and Aline B. Scandurro. (2009) The human pro-inflammatory peptide, LL-37, recruits multipotent mesenchymal stem/progenitor cells to ovarian tumors and promotes their differentiation and immunomodulatory properties. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3806-11. Epub 2009 Feb 20.PNAS in press.
  • Seth B. Coffelt, Kevin J. Zwezdaryk, Suzanne L. Tomchuck, Elizabeth S. Danka, and Aline B. Scandurro. (2008) The antimicrobial peptide LL-37 utilizes the FPRL1 receptor on ovarian cancer cells to activate oncogenic signaling pathways and gene expression. Mol. Can Res in press

 

Back to the top

Diane A. Blake, Ph.D.

Professor of Biochemisty
TCC Contributing Member
blake@tulane.edu
Lab homepage: http://www.som.tulane.edu/labs/blake
1430 Tulane Ave., Box SL-43, New Orleans, LA 70112-2699
(504) 988-2478, (504) 988-2684 fax



Biographical Narrative:

Dr. Blake received her B.S. in Biochemistry in 1972 from Ohio State University in Columbus, Ohio. She then moved to the University of Illinois at Urbana-Champaign to study proteoglycan biosynthesis/structure with H. Edward Conrad and received her PhD in Biochemistry in 1977. After a 4-year postdoctoral fellowship studying lectin biochemistry and glycoprotein synthesis with Irwin J. Goldstein at the University of Michigan, Ann Arbor, MI, she joined Miles Laboratories as a Research Scientist in 1981. In 1983 she took a faculty position at Meharry Medical College in Nashville, TN, where she remained for 9 years. She came to Tulane in 1993 and is now Professor of Biochemistry. Dr. Blake has published over 50 papers in the areas of glycoprotein/proteoglycan biochemistry and protein-ligand interactions. She served for 5 years as a Member of the Advisory Panel for Cell Biology for the National Science Foundation and recently was a Panel Member for their Biocomplexity initiative. She has also served on Review Panels of the Environmental Protection Agency and performed ad hoc reviews for the National Institutes of Health, the Wellcome Trust (UK), and the North Carolina Biotechnology Center. She reviews regularly for Investigative Ophthalmology and Visual Sciences and Analytica Chemistry. One area of Dr. Blake's research is focused upon a study of extracellular matrix and cell-matrix interactions. Her most recent projects have included signal transduction via extracellular matrix receptors, and research on the effects of extracellular molecules on cell migration and proliferation. She has concentrated upon those extracellular matrix molecules that influence the behavior of vascular endothelial cells. A practical outcome of her experiments has been the development of new drugs (based on extracellular matrix molecules) that inhibit the process of angiogenesis. Such angiogenesis inhibitors have applications in the control of both cancer and ocular disease. A second area of active research in Blake's laboratory is the development of antibody reagents that can be used to assess human exposure to heavy metals. Some of the antibodies she has developed for this project also have applications in cancer prognosis and therapy.



Selected Publications:
  • Blake II RC, Pavlov AR, Blake DA. Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution. Anal Biochem 272:123-134 (1999)
  • Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD, and Blake DA. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest Ophthalmol Vis Sci 41:2378-2388 (2000)
  • Muhitch JW, O'Connor KC, Blake DA, Lacks DJ, Rosenzweig N, Spaulding GF. Characterization of aggregation and protein expression of bovine corneal endothelial cells as microcarrier cultures in a rotating-wall vessel. Cytotechnol 32:253-263 (2000)
  • Darwish IA , Blake DA. Development and validation of a sensitive one-step immunoassay for determination of cadmium in human serum. Anal Chem 74:52-58 (2002)
  • Blake II RC, JDelehanty JB, Khosraviani M, Yu H, Jones RM, Blake DA. Allosteric binding properties of a monoclonal antibody and its Fab fragment. Biochemistry 42:497-598 (2003)
  • Blake II RC, Pavlov AR, Khosraviani M, Ensley HE, Kiefer GE, Yu H, Li X, Blake DA. Novel monoclonal antibodies with specificity for chelated uranium(VI): Isolation and binding properties. Bioconjugate Chemistry 15:1125-1136 (2004)
  • Glass TR, Ohmura N, Saiki H, Blake DA, Blake II RC, Lackie SJ. Use of excess solid phase capacity in immunoassays: Advantages for semi-continuous, near real time measurements and for analysis of matrix effects. Anal Chem 76:767-772 (2004)

Back to the top

Marcelo Blaya , M.D.

Assistant Professor of Medicine, Section of Hematology and Medical Oncology
TCC Contributing Member
mblaya@tulane.edu
(504) 988-5482, (504) 988-5483 fax
1430 Tulane Ave., Box SL-78, New Orleans, LA 70112-2699

 

 

Biographical Narrative:

Dr. Blaya received his medical degree in 1997 from the Pontificia Universidade Catolica do Rio Grande do Sul, Brazil. He went on to complete an Internal Medicine Residency at Hospital Sao Lucas da PUC, 1998-1999. Dr. Blaya then continued his training in internal medicine at Jackson Memorial Hospital, University of Miami, 2001-2004, where he received the Eric Reiss Award for Outstanding Teaching. During his fellowship (2004-2007), Dr. Blaya participated actively in the development of several clinical research projects at Sylvester Comprehensive Cancer Center in Miami, Florida. His major interest has been the development of Phase I and Phase II clinical trials for GI malignancies, such as pancreatic cancer, colorectal cancer and gastric cancer. Dr. Blaya has also been involved in several clinical projects focusing on lung and breast cancer. He joined the Tulane University faculty as an assistant professor of medicine in the Section of Hematology and Medical Oncology in 2007. At Tulane, Dr. Blaya is involved in the training of medical students, residents and fellows. He is also an active member of several medical societies, including the American Society of Clinical Oncology, the American Society of Hematology and the American Medical Association.



Selected Publications:

  • Lossos IS, Morgenzstern D, Blaya M, Alencar A, Pereira D, Rosenblatt J. Rituximab for treatment of chemo-immunotherapy naive marginal zone lymphoma. Leuk Lymphoma, 48(8): 1630-2, 2007.
  • Blaya M, Calfa C, Silva O. Prognostic factors in breast cancer. In Tratado de Patologia Mamario, 2nd ediccion, Mexico, 2007.
  • Blaya M, Santos E, Roman E, Karr M, Raez L. Lung cancer in women, Nova Publishers, 2007.
  • Blaya M. Neoadjuvant hormonal therapy in prostate cancer. In Prostate Cancer - A Practical Guide. O. Silva, et al. (eds.), Elsevier, 2007.
  • Roman E, Blaya M, Han HS, Biagioli M, Harvey M, Markoe M, Raez LE. Re-irradiation with IMRT and chemotherapy for recurrent head and neck cancer. J of Thor Onc, 1(8): 919a, 2006.
  • Raez LE, Bepler G, Lopes G, Blaya M, Lobo C, Macintyre J, Farfan N, Flores A, Walker G, Rocha-Lima C. Phase II trial of fixed dose rate (FDR) gemcitabine (G) in combination with oxaliplatin (O) in the 2nd line treatment of patients with advanced and metastatic non-small cell lung cancer. J of Thor Onc, 1(8): 901, 2006.
  • Roman E, Raez L, Biagioli M, Harvey M, Blaya M, Tolba K, Bathia R, Markoe A. Re-irradiation with concurrent chemotherapy for recurrent head and neck cancer. J Clin Oncol, 24(18s): 294s, 2006.
  • Blaya M. Translated chapter on Gastrointestinal Conditions for publishing in Portuguese. In Psychological Factors Affecting Medical Conditions. Alan Stoudemire, M.D., ed. American Psychiatric Publishing, 1995.

Back to the top

Erin Boh, M.D.

Professor of Dermatology
Joseph Chastain Professorship of Clinical Dermatology
Director of Dermatology Clinic at Charity Hospital MCLNO
TCC Associate Member
eboh@tulane.edu
(504) 988-5114, (504) 988-7382 fax
1430 Tulane Ave., Box TB-36, New Orleans, LA 70112-2699



Biographical Narrative:

Dr. Boh received her B.S. from Auburn University in 1973. She completed her Ph.D. studies in 1980 under Dr. Richard Steele at Tulane University, Department of Biochemistry. She then completed a year-long fellowship with the American Heart Association. Dr. Boh entered the Tulane University School of Medicine in 1981 and received her M.D. in 1985. She completed her internship at Tulane University/Charity Hospital Affiliated Programs in 1986 and completed a Dermatology Residency at Parkland Hospital in 1989. In 1989 she was Chief Resident of her Dermatology Program. Dr. Boh joined the Tulane faculty in 1990 as an Assistant Professor and is now an Associate Professor of Dermatology. Dr. Boh's research has focused on photobiology and chronic diseases such as psoriasis and skin cancers such as lymphoma. She is an international expert in photopheresis and has a strong interest in cutaneous T-Cell lymphomas and cutaneous manifestations of internal disease, both in the pediatric and adult population. In addition to participating in a number of studies in lymphoma, Dr. Boh has conducted studies on psoriasis and other chronic dermatologic diseases.


Selected Publications:

  • Fucich LF, Freeman SM, Boh EE, McBurney EI, Marrogi AJ. Quantitative immunophenotyping and gene rearrangement analysis in 59 cases of atypical cutaneous lymphoid infiltrates. Am J Cutan Pathol 23: 50 (1996)
  • Fucich LF, Freeman SM, Boh EE, McBurney EI, Marrogi AJ. Atypical Cutaneous Lymphocytic Infiltrate and a Role for Quantitative Immunohistochemistry and Gene Rearrangement Studies. Int J Derm 38: 749-756 (1999)
  • Karukonda SRK, Boh EE, McBurney EI, Russo GG, Flynn TC, Millikan LE. The Effects of Drugs on Wound Healing: Phases of Wound Healing, Cytokine Therapy, Local Factors and Pharmacologic Interactions, Part I. Int J Derm 39(4): 250-257 (2000)
  • Karukonda SRK, Boh EE, McBurney EI, Russo GG, Flynn TC, Millikan LE. The Effects of Drugs on Wound Healing: Specific Classes of Drugs and Their Effect on Wound Healing, Part II. Int J Derm 39(5): 321-333 (2000)
  • Ward HA, Russo GG, McBurney EI, Millikan LE, Boh EE. Post-Transplant Primary Cutaneous T-Cell Lymphoma: A Case Presentation and Review of the Literature. J Amer Acad Derm 44: 675-680 (2001)

Back to the top

Bruce A. Bunnell , Ph.D.

Professor of Pharmacology
TCC Associate Member
bbunnell@tulane.edu
(504) 988-3329, (504) 988-7710 fax
1430 Tulane Ave., Box SL-99, New Orleans, LA 70112

Biographical Narrative:

Dr. Bruce A. Bunnell is a professor of pharmacology at the Tulane University Health Sciences Center and chairman, Division of Gene Therapy at the Tulane National Primate Research Center. He received his undergraduate education at Purdue University and his graduate training in molecular genetics at the University of Alabama at Birmingham (PhD, 1990). He did his postdoctoral training at the University of Michigan, and advanced training as a senior staff fellow at the National Human Genome Research Center at the National Institutes of Health. Dr. Bunnell held faculty positions at the Ohio State University (1998 - 2002). He joined the School of Medicine at Tulane University in 2002. Dr. Bunnell's research interests have focused on the development of gene and stem cell based therapies for lysosomal storage diseases (Sandhoff and Krabbe disease). His group is also interested in defining the biologic properties that control the stem-cell characteristics of mesenchymal stem cells.

Selected Publications:

  • Izadpanah R, Joswig T, Dufour J, Kirijan JC, Bunnell BA. Isolation and preliminary characterization of multipotential mesenchymal stem cells from the bone marrow of rhesus macaques. Stem Cells and Development, 14:440-451, 2005.
  • Cho H, Kim Y, Kim S, Bae Y, Kim J. Bunnell BA, Jung J. Endogenous Wnt signaling promotes proliferation and suppresses osteogenic differentiation in human adipose derived stromal cells. Tissue Engineering, 12:111-121, 2006.
  • Bunnell BA, Ylostalo J, Kang SK. Common transcriptional gene profile in neurospheres derived from pATSCs, pBMSCs, and pNSCs. Biochem Biophys Res Commun, 343:762-771, 2006.
  • Grayson WL, Zhao F, Izadpanah R, Bunnell BA, Ma T. Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. J. Cell Physiol, 207: 331-339, 2006.
  • Davis SF, Hood JL, Bunnell BA. Isolation of adult rhesus neural stem and progenitor cells and differentiation into immature oligodendrocytes. Stem Cells and Development, 15:191-199, 2006.

Back to the top

Carol A. Burdsal, Ph.D.

Associate Professor of Cell & Molecular Biology
TCC Contributing Member
cburdsal@tulane.edu
Homepage on the CMB website: http://cell.tulane.edu/Burdsal/index.htm
(504) 862-3163, (504) 865-6785 fax
2000 Stern Hall, 6400 Freret St., New Orleans, LA 70118



Biographical Narrative:

Dr. Burdsal received her B.S. in Biology from the University of Miami at Coral Gables, FL in 1983. She then carried her doctoral research in the laboratory of Dr. David R. McClay at the Duke University on cell and adhesion and pattern formation in embryonic development. She received her Ph. D. in 1990 and then moved to the laboratory of Dr. Roger A. Pedersen at the University of California, San Francisco. There she carried out her postdoctoral research from 1990-1995 focusing on how changes in cell adhesion regulate mammalian development. In 1995, she joined the faculty of the Department of Cell and Molecular Biology at Tulane University and she reached the rank of Associate Professor in 2001. The major focus of Dr. Burdsal1s research is how growth factor signaling regulates cell-cell interactions in the developing mouse embryo. Her laboratory examines how gene expression is regulated in response to growth factor signaling during early development and organogenesis. Dr. Burdsal's lab also studies how growth factor signaling affects the cell-extracellular matrix interactions of cancer cells.



Selected Publications:

  • Burdsal CA, Flannery ML, Pedersen RA. FGF-2 alters the fate of mouse epiblast from ectoderm to mesoderm in vitro. Dev Biol 198, 231-244 (1998)
  • Burdsal CA and Ceasar JA. FGF-2 differentially alters the Cell-ECM interactions of colon carcinoma cells which vary in metastatic potential. Mol Biol Cell 9, 431a (1998)
  • Alappat SR, Zhang M, Zhou X, Alliegro MA, Alliegro MC, Burdsal CA. Mouse pigpen encodes a nuclear protein whose expression is developmentally regulated during craniofacial morphogenesis. Mol Biol Cell 11, 55a (2000)
  • Boucher DM, Shaeffer M, Gold JD, Burdsal CA, Meneses JJ., Pedersen RA, Blum M. Goosecoid expression represses brachyury in embryonic stem cells and affects craniofacial development. Int J Dev Biol 44, 279-288 (2000)
  • Martinez-Ceballos E, Burdsal CA. Differential expression of chicken CYP26 in anterior versus posterior limb bud in response to retinoic acid. J Exp Zool 290:136-147 (2001)
  • Alappat SR, Zhang M, Zhao X, Alliegro MA, Alliegro MC, Burdsal CA. Mouse pigpen encodes a nuclear protein whose expression is developmentally regulated during craniofacial morphogenesis. Dev Dyn 228:59-71 (2003)

Back to the top

Matthew E. Burow, Ph.D.

Assistant Professor of Medicine
Section of Hematology and Medical Oncology
Adjunct Assistant Professor of Surgery
TCC Program Member
mburow@tulane.edu
(504) 988-6688, fax (504) 988-5483
1430 Tulane Ave., Box SL-78, New Orleans, LA 70112
Lab homepage:
http://www.som.tulane.edu/medhemonc/members/MBUR/index.html



Biographical Narrative:

Dr. Burow received his B.S. in Biology in 1994 at the University of Southern Mississippi. He completed his Ph.D. in 1998 at Tulane University from the Interdisciplinary Graduate Program in Molecular and Cellular Biology. Dr. Burow carried out his post-doctoral studies with Dr. John McLachlan at the Tulane/Xavier Center for Bioenvironmental Research. He was appointed in 2000 as a Research Assistant Professor in the Department of Pharmacology. In 2002 Dr. Burow accepted his current position as an Assistant Professor in the Section of Hematology and Medical Oncology, Department of Medicine with an appointment as an Adjunct Assistant Professor in the Department of Surgery. Dr. Burow's primary research interests focus on understanding the molecular mechanisms that control estrogen receptor mediated gene expression and anti-estrogen resistance in breast carcinoma cells and the way that cell survival and apoptotic signaling pathways regulate the progression of breast carcinoma to a hormone independent and drug resistant phenotype.



Selected Publications:

  • Burow ME, Weldon CB, Collins-Burow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S, Beckman BS. Cross-talk between phosphatidylinositol-3 kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem 275(13): 9628-9635 (2000)
  • Burow ME, Weldon CB, Melnik LI, BN Duong, Collins-Burow BM, Klippel A, Beckman BS, McLachlan JA. Phosphatidylinositol 3-kinase/AKT mediated regulation of NF-_B signaling events as a mechanism for suppression of TNF-induced apoptosis. Biochem and Biophys Res Comm 271: 342-345 (2000)
  • Burow ME, Boue BS, Collins-Burow BM, Melnik LI, Duong BN, Li SF, Wiese T, Cleavland E, McLachlan JA. Phytochemical glyceollins, isolated from soy, mediate anti-hormonal effects through estrogen receptor alpha and beta. J Clin Endocrinol Metab 86(4): 1750-1758 (2001)
  • Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS. Oestrogen-mediated suppression of TNF-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. J Steroid Biochem Mol Bio 78(5): 409-418 (2001)
  • Frigo DE, Duong BN, Melnik LI, Schief L, Collins-Burow BM, Pace DK, McLachlan JA, Burow ME. Flavonoid phytochemicals regulate activator Protein-1 signal transduction pathways in endometrial and kidney stable cell lines. J Nutr 132(7): 1848-1853 (2002)
  • Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott SE, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132(2):293-301 (2002)
  • Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow ME, Gordon A, Dhurandhar NM, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine 9(5): 562-567 (2003)
  • Simstein R, Burow ME, Parker A, Weldon CB, Beckman BS. "Apoptosis, Chemoresistance and Breast Cancer: Insights from the MCF-7 Cell Model System". Exp Biol Med 228(9):995-1003 (2003)
  • Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA. Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis 25(2): 249-261 (2004).
  • Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond TG, Tang Y, Beckman BS. Novel Ceramide Analogues as Potential Chemotherapeutic Agents in Breast Cancer. J Pharmacol Exp Therapeut 309(2): 523-532 (2004).
  • Weldon CB, Parker AP Patten D, Elliot S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 24(6): 1473-1480 (2004).
  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng PC, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Daniel B, Gordon A, Myers L, Disis ML, Knuston K, Lackner A, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10(9):942-949 (2004)


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Back to the top

 

Our Partners

Information for Researchers
 
more info »
 

Latest News
 
more news »